Clinical Trial Update: Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of VIP943 in adults with advanced CD123+ hematologic malignancies is currently recruiting, including acute myeloid leukemia, B-cell acute lymphobl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• B-cell Acute Lymphoblastic Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• VIP943

Snippet

Sponsor: Vincerx Pharma, Inc. | Conditions: Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia | Phase 1 | Status: RECRUITING